Compare Abeona Therapeutics Inc (ABEO) vs AngloGold Ashanti Limited (AU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs AngloGold Ashanti Limited — how do they compare? Abeona Therapeutics Inc trades at $6.77 (market cap $373.32M), while AngloGold Ashanti Limited trades at $79.54 (market cap $41.50B). The key difference: AngloGold Ashanti Limited is far larger — about 111.2× Abeona Therapeutics Inc's market cap, and AngloGold Ashanti Limited pays a 5.6% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | AU | |
|---|---|---|
Market Cap | $373.32M | $41.50B |
Sector | Health | Basic Materials |
52-Week High | $7.23 | $128.26 |
52-Week Low | $4.17 | $45.22 |
Enterprise Value | $228.22M | $40.63B |
Dividend Yield | — | 5.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
AngloGold Ashanti (AU) trades at $82.01, down 3.12% on the day, near key support at $81. The stock shows strong fundamentals with 2025 revenue surging to $9.89B and net income reaching $2.64B, driving a robust 31.11% net margin. Recent Q1 2026 earnings beat expectations at $2.52 EPS, while the company announced a $1.16 dividend and a share repurchase program. Technical indicators signal bearish momentum with RSI at 80.83 suggesting overbought conditions, but analyst consensus remains bullish with a $118 price target.
Outlook is positive due to explosive revenue growth, high profitability, and shareholder returns, but risks include gold price volatility and execution challenges. The stock offers value with a P/E of 12.34, though technical weakness may pressure near-term performance. Institutional sentiment is supportive with 64% buy ratings, but investors should monitor gold market dynamics and cost inflation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About AngloGold Ashanti Limited
Anglogold Ashanti Ltd is one of the largest gold miners. The company also produces silver and sulphuric acid as by-products. Its operating divisions are Africa, Australia, and the Americas. The firm generates a majority of its revenue from Africa which includes Ghana, Guinea, Mali, the Democratic Republic of the Congo, and Tanzania.
Read more on AU →
